EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preferences between three options for androgen deprivation therapy: a focus group study

Hannah L Rush iD, Sophie Merrick, John Marshall, John Deighan, Hoda Abdel-Aty, Abdulla Alhasso, Noel W Clarke, Roger Kockelbergh iD, Stephen Mangar, Stuart D Rosen, Nicholas D James, Duncan C Gilbert iD und 2 weitere

BJU International · 2025

DOI: 10.1111/bju.16863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Hannah L Rush und 13 weiteren Autor:innen. Beteiligte Einrichtung: MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Patient Preference, Androgen Antagonists, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone‐releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists. This study aimed to identify whether this is an important choice for men, which treatment men would choose if offered either LHRH agonist injections, tE2 patches or oral LHRH antagonists as ADT, and to explore the factors influencing this decision. Subjects, Patients, and Methods Five focus groups were conducted. A total of 24 men from around the UK participated in discussions, of whom 10 had never had prostate cancer and 14 had early prostate cancer but had not received ADT. Focus groups were co‐facilitated with patient and public involvement representatives. Transcripts were analysed using a critical realist thematic analysis approach.

Results

Participants reported that having a choice of ADT is important and being involved in making treatment decisions can help men maintain an element of control. Most men expressed a preference to avoid ADT with LHRH agonist injections; 14 of the 24 men reported they would choose an oral LHRH antagonist, eight reported they would choose tE2 patches, and two that they would choose LHRH agonist injections. Participants reported a large number of factors that influenced their treatment choice that were grouped into: (i) side‐effects of treatment, (ii) logistical aspects, and (iii) advice from trusted others. Personal preferences between different types of ADT were based on factors that participants identified as important to them, this prioritisation of factors was influenced by participants’ past experiences, current health beliefs, and future expectations.

Conclusions

Men wish to have choice of ADT, and many would not choose LHRH agonists injections if there were other ADT options available. This should be considered, as reimbursement committees and guideline‐makers consider the role of alternative ADT strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPatient PreferenceAndrogen AntagonistsGonadotropin-Releasing HormoneEstradiolHumansMaleAgedMiddle AgedFocus GroupsAdministration, CutaneousAdministration, OralAged, 80 and over

Stichwörter der Autor:innen

LHRH agonistsandrogen deprivation therapyfocus group studypatient choicerelugolixtransdermal oestradioltreatment decision‐making

Substanzen

Androgen AntagonistsGonadotropin-Releasing HormoneEstradiol

Autor:innen und Institutionen

  • MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Guy's and St Thomas' Foundation Trust, London, UK.
  • Patient and Public Representatives for the PATCH Trial, London, UK.
  • The Institute of Cancer Research, London, UK.
  • The Royal Marsden NHS Foundation Trust, London, UK.
  • The Beatson West of Scotland Cancer Centre, Glasgow, UK.

ORCID-Profile: Hannah L Rush, Roger Kockelbergh, Duncan C Gilbert, Annabelle South

Förderung

  • Medical Research Council
  • Cancer Research UK

Zitieren

APA

Rush, H. L., Merrick, S., Marshall, J., Deighan, J., Abdel-Aty, H., Alhasso, A., Clarke, N. W., Kockelbergh, R., Mangar, S., Rosen, S. D., James, N. D., Gilbert, D. C., South, A., & Langley, R. E. (2025). Preferences between three options for androgen deprivation therapy: a focus group study. BJU International. https://doi.org/10.1111/bju.16863

Vancouver

Rush HL, Merrick S, Marshall J, Deighan J, Abdel-Aty H, Alhasso A, et al. Preferences between three options for androgen deprivation therapy: a focus group study. BJU International. 2025. doi:10.1111/bju.16863

BibTeX
@article{Rush2025,
  author = {Rush, Hannah L and Merrick, Sophie and Marshall, John and Deighan, John and Abdel-Aty, Hoda and Alhasso, Abdulla and Clarke, Noel W and Kockelbergh, Roger and Mangar, Stephen and Rosen, Stuart D and James, Nicholas D and Gilbert, Duncan C and South, Annabelle and Langley, Ruth E},
  title = {Preferences between three options for androgen deprivation therapy: a focus group study},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16863}
}
Kostenlos starten →